Delivery Order SPE2DB22D1017-SPE2DB25FG8UK
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ibrance 75 mg capsules (21-count packages) with a ceiling value of $8,123.96. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The award is...
- The Defense Logistics Agency awarded a $8,118.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ibrance 125 mg capsules (21-count units). This non-set-aside, competitively awarded contract specifies an ultimate completion date of August 28, 2025, and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $8,118.08 firm fixed price delivery order to AmerisourceBergen Drug Corp for Ibrance 125 mg capsules (21-count) on July 21, 2025, with an ultimate completion date of August 11, 2025. The contract, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitively awarded procurement from the company's existing pharmaceutical supply agreement...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for 21 capsules of Ibrance 125 mg, a prescription oncology medication used in cancer treatment. Issued on July 29, 2025, with an ultimate completion date of August 19, 2025, this firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement with no small business restrictions. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7) on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the prime contractor, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication used...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for Ibrance 75 mg capsules (21-count unit) on July 22, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication used in cancer treatment, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $16,244.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count) on August 5, 2025, with an ultimate completion date of August 26, 2025. This firm fixed price, non-set-aside contract reflects a routine pharmaceutical procurement to support federal medical supply needs. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99...
- This delivery order, awarded July 30, 2025, by the Defense Logistics Agency's Medical Supply Chain to AmerisourceBergen Drug Corp, provides for the supply of Ibrance 75 mg tablets in quantities of seven tablets per unit. The contract, valued at $64,987.24 with a firm fixed price structure, is scheduled for completion by August 20, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity of seven units). This firm fixed-price delivery order, issued on July 25, 2025, carries an ultimate completion date of August 15, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ibrance (palbociclib) is a cyclin-dependent...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG8UKDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ibrance 125 mg capsules (21-count packages) under a firm fixed-price contract valued at $8,118.08, with completion scheduled for August 22, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor within the DLA's medical supply chain. The product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that authorizes the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Ibrance, a specialty oncology medication, exemplifies the brand-name pharmaceutical products that AmerisourceBergen delivers through this vehicle to support the Defense Health Agency and other federal healthcare systems. The firm's demonstrated capability in managing substantial pharmaceutical procurement volumes through competitive awards positions it as a key provider within the DLA's evolving medical vendor strategy.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 8/1/25 |